Advertisement

Head and neck mucosal melanoma: The United Kingdom national guidelines

Published:August 20, 2020DOI:https://doi.org/10.1016/j.ejca.2020.07.017

      Highlights

      • All head and neck mucosa melanomas are classified as stage III-IV.
      • Prognosis is driven by distant metastases.
      • There is a role of ICI or targeted therapies as adjuvant treatment.
      • Adjuvant RT should be only offered in highly selected patients.
      • Consider entry to clinical trials to all patients.

      Abstract

      The United Kingdom head and neck mucosal melanoma guideline development group used an evidence-based systematic approach to make recommendations in key areas of uncertainty in the field, including accurate diagnosis and staging; the appropriate treatment pathway including surgery, adjuvant radiation and new systemic treatments, such as targeted agents and immunotherapy; and the surveillance of patients after treatment. The guidelines were sent for international peer review and have been accredited by the National Institute for Health and Care Excellence. A summary of key recommendations is presented. The full documents are available on the Melanoma Focus website (https://melanomafocus.com/activities/mucosal-guidelines/mucosal-melanoma-resources/).

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Ascierto P.A.
        • Accorona R.
        • Botti G.
        • Farina D.
        • Fossati P.
        • Gatta G.
        • et al.
        Mucosal melanoma of the head and neck.
        Crit Rev Oncol Hematol. 2017 Apr; 112: 136-152
        • Lawaetz M.
        • Birch-Johansen F.
        • Friis S.
        • Eriksen J.G.
        • Kiss K.
        • Gade S.
        • et al.
        Primary mucosal melanoma of the head and neck in Denmark, 1982-2012: demographic and clinical aspects. A retrospective DAHANCA study.
        Acta Oncol (Madr). 2016; 55: 1001-1008
        • Iida Y.
        • Salomon M.P.
        • Hata K.
        • Tran K.
        • Ohe S.
        • Griffiths C.F.
        • et al.
        Predominance of triple wild-type and IGF2R mutations in mucosal melanomas.
        BMC Canc. 2018; 18: 1-10
        • Amit M.
        • Tam S.
        • Takahashi Y.
        • Bell D.
        • Roberts D.
        • Hanna E.
        Mutation status in sinonasal mucosal melanoma.
        J Neurol Surg Part B Skull Base Conf 27th Annu Meet North Am Skull Base Soc United States. 2017; 78
        • Lyu J.
        • Wu Y.
        • Li C.
        • Wang R.
        • Song H.
        • Ren G.
        • et al.
        Mutation scanning of BRAF , NRAS , KIT, and GNAQ/GNA11 in oral mucosal melanoma: a study of 57 cases.
        J Oral Pathol Med. 2016 Apr; 45: 295-301
        • Ozturk Sari S.
        • Yilmaz I.
        • Taskin O.C.
        • Ozluk Y.
        • Buyukbabani N.
        Clinicopathologic and molecular features of mucosal melanoma: data from a tertiary care center.
        Virchows Arch. 2016; 469: S200
        • Schaefer T.
        • Satzger I.
        • Gutzmer R.
        Clinics, prognosis and new therapeutic options in patients with mucosal melanoma: a retrospective analysis of 75 patients.
        Medicine (Baltim). 2017; 96e5753
        • Yde S.S.
        • Sjoegren P.
        • Heje M.
        • Stolle L.B.
        Mucosal melanoma: a literature review.
        Curr Oncol Rep. 2018; 20: 28
        • Wenig B.M.
        Laryngeal mucosal malignant melanoma. A clinicopathologic, immunohistochemical, and ultrastructural study of four patients and a review of the literature.
        Cancer. 1995; 75: 1568-1577
        • Lopez-Graniel C.M.
        • Ochoa-Carrillo F.J.
        • Meneses-Garcia A.
        Malignant melanoma of the oral cavity: diagnosis and treatment experience in a Mexican population.
        Oral Oncol. 1999; 35: 425-430
        • Chan R.C.
        • Chan J.Y.
        • Wei W.I.
        Mucosal melanoma of the head and neck: 32-year experience in a tertiary referral hospital.
        Laryngoscope. 2012; 122: 2749-2753
        • Ballantyne A.J.
        • Moore G.
        • Smart C.
        • Phillips T.
        • Fairley G.
        • Bodenham D.
        • et al.
        Malignant melanoma of the skin of the head and neck. An analysis of 405 cases.
        Am J Surg. 1970 Oct 1; 120: 425-431
        • Prasad M.L.
        • Busam K.J.
        • Patel S.G.
        • Hoshaw-Woodard S.
        • Shah J.P.
        • Huvos A.G.
        Clinicopathologic differences in malignant melanoma arising in oral squamous and sinonasal respiratory mucosa of the upper aerodigestive tract.
        Arch Pathol Lab Med [Internet]. 2003; 127: 997-1002
        • Luna-Ortiz K.
        • Aguilar-Romero M.
        • Villavicencio-Valencia V.
        • Zepeda-Castilla E.
        • Vidrio-Morgado H.
        • Peteuil N.
        • et al.
        Comparative study between two different staging systems (AJCC TNM VS BALLANTYNE’S) for mucosal melanomas of the Head & Neck.
        Med Oral Patol Oral Cir Bucal. 2016 Jul 1; 21 (30): e425
        • Brierley J.
        • Gospodarowicz M.K.
        • Mary K.
        • Wittekind C (Christian)
        TNM classification of malignant tumours.
        8th ed. 2017
        • Lydiatt W.
        • Brandwein-gensler M.
        • Kraus D.
        Mucosal melanoma of the head and neck.
        in: AJCC cancer staging manual. 8th ed. 2017: 163-169
        • Thompson L.
        • Franchi A.
        • Helliwell T.
        • Muller S.
        • Williams M.
        Mucosal melanomas of the head and neck, histopathology reporting guide.
        1st ed. International Collaboration on Cancer Reporting, Sydney2018
        • Amit M.
        • Tam S.
        • Abdelmeguid A.S.
        • Kupferman M.E.
        • Su S.Y.
        • Raza S.M.
        • et al.
        Patterns of treatment failure in patients with sinonasal mucosal melanoma.
        Ann Surg Oncol. 2018; 25: 1723-1729
        • Bakkal F.K.
        • Basman A.
        • Kizil Y.
        • Ekinci O.
        • Gumusok M.
        • Ekrem Zorlu M.
        • et al.
        Mucosal melanoma of the head and neck: recurrence characteristics and survival outcomes.
        Oral Surg Oral Med Oral Pathol Oral Radiol. 2015; 120: 575-580
        • Amit M.
        • Na’ara S.
        • Hanna E.Y.
        Contemporary treatment approaches to sinonasal mucosal melanoma.
        Curr Oncol Rep. 2018; 20: 10
        • Cao W.
        • Guan B.
        • Yu A.
        • Xu L.
        • Wang Y.
        • Kafle S.
        • et al.
        Treatment and outcomes of endoscopic surgery and traditional open resection in sinonasal mucosal melanoma.
        Acta Otolaryngol. 2017; 137: 862-867
        • Wang X.
        • Wu H.M.
        • Ren G.X.
        • Tang J.
        • Guo W.
        Primary oral mucosal melanoma: advocate a wait-and-see policy in the clinically N0 patient.
        J Oral Maxillofac Surg. 2012; 70: 1192-1198
        • Li W.
        • Yu Y.
        • Wang H.
        • Yan A.
        • Jiang X.
        Evaluation of the prognostic impact of postoperative adjuvant radiotherapy on head and neck mucosal melanoma: a meta-analysis.
        BMC Canc. 2015; 15: 758
        • Jarrom D.
        • Paleri V.
        • Kerawala C.
        • Roques T.
        • Bhide S.
        • Newman L.
        • et al.
        Mucosal melanoma of the upper airways tract mucosal melanoma: a systematic review with meta-analyses of treatment.
        Head Neck. 2017; 39: 819-825
        • Weber J.
        • Mandala M.
        • Del Vecchio M.
        • Gogas H.J.
        • Arance A.M.
        • Cowey C.L.
        • et al.
        Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma.
        N Engl J Med. 2017 Nov 9; 377: 1824-1835
        • Long G.V.
        • Hauschild A.
        • Santinami M.
        • Atkinson V.
        • Mandalà M.
        • Chiarion-Sileni V.
        • et al.
        Adjuvant dabrafenib plus trametinib in stage III BRAF -mutated melanoma.
        N Engl J Med. 2017 Nov; 2377: 1813-1823
        • Moya-Plana A.
        • Auperin A.
        • Obongo R.
        • Baglin A.
        • Ferrand F.R.
        • Baijat B.
        Oncologic outcomes, prognostic factor analysis and therapeutic algorythm evaluation of head and neck mucosal melanomas in France.
        Eur J Canc. 2019 Dec; 123: 1-10
        • D'Angelo S.P.
        • Larkin J.
        • Sosman J.A.
        • Lebbé C.
        • Brady B.
        • Neyns B.
        • et al.
        Efficacy and safety of nivolumab alone or in combination with ipilimumab in patients with mucosal melanoma: a pooled analysis.
        J Clin Oncol. 2017 Jan 10; 35: 226-235
        • Shoushtari A.N.
        • Wagstaff J.
        • Ascierto P.A.
        • Butler M.O.
        • Lao C.D.
        • et al.
        CheckMate 067: long-term outcomes in patients with mucosal melanoma.
        J Clin Oncol. 2020; 38 (10019-10019)
        • Sheng X.
        • Yan X.
        • Chi Z.
        • Si L.
        • Cui C.
        • Bixia T.
        • et al.
        Axitinib in combination with toripalimumab, a humanized immunoglobulin G4 monoclonal antibody against Programmed Cell Death-1, in patients with metastatic mucosal melanoma: an open-label phase IB trial.
        J Clin Oncol. 2019 Nov; 37: 2987-2999
        • Hodi F.S.
        • Corless C.L.
        • Giobbie-Hurder A.
        • Fletcher J.A.
        • Zhu M.
        • Marino-Enriquez A.
        • et al.
        Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.
        J Clin Oncol. 2013 Sep 10; 31: 3182-3190